Abstract:ObjectiveTo construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.MethodsT cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD 50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD 50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI- msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.ResultsA recombinant strain named LI- msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD 50 value of LI- msv for C57BL/6 mice (i.v.) was 3.3×10 8 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ + CD4 + and IFN-γ + CD8 +T lymphocytes were successfully induced in LI -msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4 + and CD8 +T cells was significantly higher than those of vector control group and NS control group ( P<0.005). Additionally, the frequency of specific TNF-α + CD4 + T cell in LI -msv immunized group was significantly higher than that of vector control ( P<0.01) and NS control group ( P<0.005), and TNF-α + CD8 + T cell frequency obviously increased than NS control group ( P<0.005).ConclusionsA novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

Construction of the Recombinant Secreted and Non-Secreted Mycobacterium-Eg95 Vaccines for Echinococcus Granolosus

Construction of the Recombinant Secretion Type BCG-Eg95 Vaccine of Echinococcus Granulosus

[Construction, Identification, and Expression of Lactococcus lactis-Based Recombinant Vaccine for Echinococcus granulosus]

[Construction and Expression of the Echinococcus Granulosus Recombinant BCG-EgG1Y162].

[Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria Ivanovii].

Cloning Sequencing of Eg95 Antigen Gene and Construction of Pcdna3-Eg95

Constructing Shuttle Plasmid Fusion Expressing Ag85B-ESAT-6 on the Surface of Mycobacterium

Construction and identification of the recombinant plasmid pET30a-EgA31-Eg95 of Echinococcus granulosus

[Construction and Immunogenicity of DNA Vaccine Encoding Secreted Form of Ag85B Protein of Mycobacterium Tuberculosis].

Construction of the Recombinant Plasimid pET30a-EgA31 of Echinococcus Granulosus and Its Induced Expression in E.coil

Cloning and prokaryotic expression of EG95 gene of Echinococcus granulosus oncospheres

[Transient Expression of Echinococcus Granulosus Eg95 DNA Vaccine and Induction of Immune Response in Mice].

Construction of the Recombinant Plasmid Pet30a-Ega31 of Echinococcus Granulosus and Its Induced Expression in E. Coli.

Identification of Combined T-cell and B-cell Reactive Echinococcus Granulosus 95 Antigens for the Potential Development of a Multi-Epitope Vaccine

Construction and identification of recombinant Mycobacterium smegmatis vaccine expressing Cysticercus cellulosae cC1 antigen]

Construction, Expression and Identification of a Recombinant BCG Vaccine Secreting the Fusion Protein CFP10- ESAT6

CLONING AND EXPRESSION OF MYCOBACTERIUM TUBERCULOSIS Ag85B IN E. COLI

Screening and construction of recombinant BCG strains expressing the Ag85B-ESAT6 fusion protein]

Recombinant Expression and Purification of Antigen 85A of Mycobacterium Tuberculosis(Mtb.)

Construction and Identification of Recombinant BCG Carrying Human Granulysin Active Peptide and Murine IL-12 Genes

Cloning and expression of Mycobacterium bovis secreted protein MPB83 in Escherichia coli.